How do you validate AI-generated medical content for accuracy?

Anthony Stackman · 21 Oct 2026

Validating AI-generated medical content requires a structured human review process led by qualified medical writers or clinicians before anything is used or published. AI tools can accelerate drafting and surface relevant information, but they cannot reliably verify clinical claims, interpret regulatory nuance, or judge whether content meets the standards required in pharmaceutical and healthcare communications. Below, we cover the specific errors to watch for, who should own the review process, which sources to use, and how to build a workflow that is both rigorous and practical.

What types of errors does AI-generated medical content typically produce?

AI-generated medical content most commonly produces factual inaccuracies, outdated clinical information, hallucinated references, and subtly misleading statistical framing. These errors are particularly dangerous because they often appear plausible and well-structured — harder to catch on a quick read than obvious mistakes.

The most serious category is hallucination: AI models can generate citations that do not exist, attribute findings to studies that never took place, or present clinical data with a confidence that has no evidential basis. Even when a real study is referenced, the model may misrepresent its findings, conflate results from different trials, or strip away the caveats that make the data meaningful in context.

Beyond fabrication, AI systems trained on large but static datasets can present guidance that has since been superseded by updated trial results, revised prescribing information, or new regulatory decisions. In fast-moving therapeutic areas such as oncology or immunology, this is a significant risk. There is also a subtler problem: AI-generated content tends to smooth over complexity. Nuanced risk-benefit discussions, population-specific considerations, and contraindications may be flattened or omitted entirely — producing content that looks accurate at a surface level but is clinically incomplete.

Who should be responsible for validating AI medical content?

Responsibility for validating AI medical content should sit with qualified medical writers and clinicians — not with the teams who prompted or generated the content. The person who commissioned or drafted the AI output is too close to it to review it objectively, and may lack the clinical training needed to identify subtle inaccuracies.

In a well-structured medcomms environment, validation typically involves at least two layers of review. A medically qualified reviewer checks clinical accuracy, appropriate use of data, and alignment with current evidence. A regulatory or compliance reviewer then assesses whether the content meets applicable codes — the ABPI Code in the UK, EFPIA guidelines across Europe, or FDA promotional regulations in the US. For content that will be seen by healthcare professionals or patients, both layers are essential.

Senior medical affairs leads or external expert advisors may also be brought in for high-stakes content: pre-launch materials, congress presentations, or publications. The key principle is that accountability must be explicit and documented. Knowing that AI was involved in drafting does not reduce the obligation on the named approver to take full responsibility for the accuracy and compliance of the final content.

What sources should be used to fact-check AI medical claims?

AI medical claims should be verified against primary sources: peer-reviewed publications, approved prescribing information, clinical trial registries, and guidance from recognised regulatory and scientific bodies. Secondary sources — including other AI-generated summaries or aggregated websites — are not appropriate for verification in a medcomms context.

For clinical data, PubMed and Embase provide access to peer-reviewed literature. For approved product information, the relevant Summary of Product Characteristics (SmPC) in Europe or the Prescribing Information in the US is the authoritative reference. Clinical trial registries such as ClinicalTrials.gov and the EU Clinical Trials Register allow reviewers to confirm whether referenced studies actually exist and whether the AI’s characterisation of their design and outcomes is accurate.

Regulatory and professional body guidance — including publications from the EMA, MHRA, FDA, and relevant learned societies — should be consulted for claims relating to treatment standards, safety signals, or disease management. Where content concerns patient populations, patient advocacy organisations and disease-specific clinical guidelines provide additional context that AI models frequently miss or misrepresent.

How do you build a structured review process for AI-assisted medcomms?

A structured review process for AI-assisted medical communications starts with defining where AI is permitted in the workflow, what outputs require review before they are shared internally, and who holds sign-off authority at each stage. Without these boundaries, AI use becomes inconsistent and validation gaps emerge.

Define the role of AI before drafting begins

Teams should agree upfront whether AI is being used for research assistance, first-draft generation, structural outlining, or editing support. Each use case carries different validation requirements. A first draft generated by AI requires more rigorous clinical review than a structural suggestion or a grammar check. Documenting AI’s role in a piece of content also supports traceability — increasingly important as regulators and industry bodies develop expectations around AI disclosure in medical communications.

Build a staged review checklist

Once AI’s role is defined, a staged checklist keeps the review process consistent. A practical structure includes an initial clinical accuracy pass against primary sources, a regulatory compliance check against applicable codes, a review for completeness — checking that important caveats, contraindications, and population limitations have not been omitted — and a final sign-off by a named, qualified approver. Each stage should be documented, with the reviewer’s identity and the date of review recorded. This creates an audit trail that supports both internal governance and any external scrutiny.

What regulatory and compliance risks apply to unvalidated AI medical content?

Unvalidated AI medical content carries real regulatory and legal risk, including potential breaches of the ABPI Code, EFPIA guidelines, FDA promotional regulations, and national advertising standards. In serious cases, publishing inaccurate or misleading medical content can result in formal complaints, mandatory corrections, reputational damage, and sanctions against the responsible company.

The regulatory frameworks governing pharmaceutical and healthcare communications make no exceptions for AI-generated content. The ABPI Code requires that all promotional and educational materials are accurate, balanced, and capable of substantiation. Whether a claim was written by a human or generated by an AI model is irrelevant to whether it meets that standard. The organisation that publishes the content is responsible for its accuracy and compliance.

There is also a broader risk around data privacy. Some AI tools process input text through external servers, which can create issues if clinical data, patient information, or commercially sensitive material is included in prompts. Organisations working in regulated healthcare environments need to assess whether the AI tools they use are compliant with GDPR, HIPAA, or other applicable data protection frameworks before integrating them into medcomms workflows.

Which AI tools and features support medical content accuracy checks?

Several AI tools and features are designed to support accuracy in medical and scientific content, including citation verification functions, retrieval-augmented generation (RAG) architectures, and specialist language models trained on clinical literature. No tool eliminates the need for human review, and all should be treated as aids rather than validators.

Retrieval-augmented generation systems are among the more reliable options for medcomms use because they generate responses by drawing on a defined, curated knowledge base rather than relying solely on training data. This reduces the risk of hallucination and makes it easier to trace claims back to their sources. Tools built on this architecture — including some enterprise AI platforms used in life sciences — allow reviewers to see which source documents informed a particular output.

Citation-checking features, available in some AI writing assistants and standalone tools, flag references that cannot be verified or that do not match the claims made in the text. These are useful as a first-pass screen but should not be treated as comprehensive. A citation may exist but still be misrepresented, and some tools check only for the existence of a reference rather than the accuracy of how it has been characterised.

Specialist models fine-tuned on biomedical literature — such as those built on PubMed datasets — tend to produce more clinically accurate outputs than general-purpose large language models for technical content. Even these require expert human review, particularly for claims relating to approved indications, safety data, or comparative efficacy.

How Wizzard helps with AI medical content validation

Wizzard is a specialist creative communications agency for pharmaceutical, health and wellbeing brands, where science is seen creatively. Our medcomms team brings together experienced medical writers, strategists, and creatives who understand both the clinical rigour and the communications craft required to produce content that is accurate, compliant, and genuinely engaging.

Medical writing and review led by qualified professionals with pharmaceutical and healthcare sector experience
Structured content governance that integrates regulatory compliance checks across ABPI, EFPIA, and other applicable frameworks
AI-assisted drafting supported by robust human validation, so speed does not come at the cost of accuracy
Full-service medcomms covering medical affairs, patient engagement, market access, and educational content
Creative execution informed by consumer advertising expertise, producing work that is bigger, brighter, and braver than expected

If your team is working out how to integrate AI responsibly into medical communications workflows without compromising accuracy or compliance, speak to Wizzard about how we approach this for our pharmaceutical and healthcare clients.

Content is for general information and communications purposes and does not constitute medical, clinical, legal or regulatory advice. Work is developed within relevant client governance, industry codes and applicable regulatory requirements in the countries and markets where Wizzard operates.